 Genprex Inc NASDAQ:GNPX said that a major cancer research center in Houston has granted it an exclusive worldwide license for an additional portfolio of six patents and one patent application and related technology for lung cancer treatment. The newly licensed intellectual property IP, which expands on a March agreement between both parties, includes methods for treating non-small cell lung cancer NSCLC by administration of a TUSC2 therapeutic in conjunction with EGFR inhibitors or other anti-cancer therapies in patients who are predicted to be responsive to TUSC2 therapy, Genprex said. 